Ikarian Capital, LLC Autolus Therapeutics PLC Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.32 - $3.36 $6,048 - $8,759	2,607 Added 1.0%	262,694 $612,000
Q3 2022 Nov 14, 2022	SELL	$2.04 - $3.76 $126,745 - $233,608	-62,130 Reduced 19.28%	260,087 $556,000
Q2 2022 Aug 12, 2022	SELL	$2.04 - $4.68 $102,000 - $234,000	-50,000 Reduced 13.43%	322,217 $912,000
Q1 2022 May 13, 2022	SELL	$3.52 - $5.46 $607,559 - $942,406	-172,602 Reduced 31.68%	372,217 $1.55 Million
Q3 2021 Nov 15, 2021	SELL	$5.32 - $7.37 $4.32 Million - $5.98 Million	-811,229 Reduced 59.82%	544,819 $3.57 Million
Q2 2021 Aug 16, 2021	BUY	$4.78 - $7.96 $478,000 - $796,000	100,000 Added 7.96%	1,356,048 $9 Million
Q1 2021 May 17, 2021	BUY	$5.49 - $9.36 $6.9 Million - $11.8 Million	1,256,048 New	1,256,048 $7.2 Million

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $205M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.